Key Takeaways on Enhancing Outcomes for mNSCLC Without Targetable Driver Mutations

Joshua K. Sabari, MD, of NYU Langone Health discusses promising results for zongertinib in HER2-mutant NSCLC; the tyrosine kinase inhibitor offers high response rates and improved quality of life with minimal toxicity.

The FDA approved datopotamab deruxtecan-dlnk (Datroway; Daiichi Sankyo) for the treatment of locally advanced or metastatic EGFR-mutated non–small cell lung cancer (NSCLC) after receipt of EGFR-directed therapy and platinum-based chemotherapy.

This next-generation ROS1 tyrosine kinase inhibitor previously received breakthrough therapy and orphan drug designations for the same patient population, as well as additional non–small cell lung cancer (NSCLC) indications.

Telisotuzumab vedotin (Teliso-V) gained FDA approval as a targeted therapy for patients with advanced non–small cell lung cancer (NSCLC) with high c-Met overexpression, offering new hope.

Phase 2 results reported at the European Lung Cancer Conference show a favorable signal for overall survival for the first-line treatment of KRAS-mutated non–small cell lung cancer (NSCLC). A phase 3 trial is enrolling now.